ArriVent BioPharma, Inc. (AVBP)
Nasdaq: AVBP · Pharmaceutical Preparations · Newtown Square, PA · filing with the SEC since 2021
Who owns ArriVent BioPharma, Inc.
As filed with the SECHolders of 5% or more
8
Infinitum Asset Management, LLC holds 9.9% of Common Stock, as its SCHEDULE 13G/A filed Feb 17, 2026 says.
Directors and officers
9
report now, of 16 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.
Holders of 5% or moreshare of the class, as filed
Infinitum Asset Management, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock · 9.9% in Aug 13, 2025
Suvretta Capital Management, LLC
SCHEDULE 13G/A · filed Aug 13, 2025 · Common Stock, $0.0001 Par Value per Share
Hillhouse Investment Management, Ltd.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 27, 2026 · Common Stock · 5.6% in Jan 21, 2026
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · 8.4% in Nov 5, 2025
Orbimed Advisors LLC
SCHEDULE 13D/A · filed Oct 8, 2026 · Common Stock · 7.5% in Aug 13, 2025
HBM Healthcare Investments (Cayman) Ltd.
SCHEDULE 13G · filed Oct 15, 2025 · Common Stock, par value $0.0001 per share
Vivo Opportunity, LLC
SCHEDULE 13G · filed Oct 13, 2026 · Common Stock, $0.0001 Par Value per Share
Octagon Capital Advisors LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.0001 par value · reported falling below 5%
Novo Holdings A/S
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.2% in Feb 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Jan 30, 2026 · Common Stock · reported falling below 5%, from 5% in Oct 30, 2025
Sofinnova Venture Partners XI, L.P. ("SVP XI")
SCHEDULE 13G/A · filed Mar 5, 2026 · Common Stock, $0.0001 Par Value per Share · reported falling below 5%
What AVBP reports owning in othersstakes of 5% or more, and other ties
ArriVent BioPharma, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 2, 2025 to Nov 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2024 runs to Nov 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 18 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Hhlr Advisors, Ltd. | 10% owner | 1 | $13.0M | 0 | 0 | $0 |